Operating profit before deduction of amortization: carismatx.com (CARM)
Carisma Therapeutics (CARM) maintains its scientific priority in the CAR-macrophage field through the maximum utilization of its sterile manufacturing capacities. The actual size of operating profit visualizes this synergy, where the level records fresh values. However, the high cost of cellular synthesis and uncertainty regarding insurance reimbursements create significant financial risks capable of destabilizing the development of this biotechnological innovator.
Carisma Therapeutics Inc. (CARM) - metric breakdowns and financial figures
- stock value and consensus price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Equity Ratio Carisma Therapeutics|CARM - Long-Term Debt to Capital|Current Liabilities to Capital Carisma Therapeutics Inc|CARM - Company Aggregate Debts|Debt to Book Value Carisma Therapeutics|CARM - Company Long-Term Debts|Company Short-Term Debts Carisma Therapeutics|Intermediate Coverage Ratio carismatx.com
- earnings and multiples data:
CARM - Net Profit|Company Profit Forecast Carisma Therapeutics|CARM - Price to Earnings Ratio|Market Cap to Projected Earnings Carisma Therapeutics Inc|CARM - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Carisma Therapeutics|CARM - Operating profit EBITDA|Net earnings per share (EPS TTM) Carisma Therapeutics|CARM - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months carismatx.com|CARM - Net earnings per share growth this year|Projected earnings per share increase next year Carisma Therapeutics
Summary company analytics:CARM - Carisma Therapeutics
To protect capital from market volatility, it is crucial for investors to distinguish random spikes from sustainable growth in operational efficiency. The bet by Carisma Therapeutics (CARM) on innovative macrophage therapies requires an analysis of the current EBITDA level, which measures net cash flow from core operations excluding debt service, allowing for an assessment of the company's real financial autonomy and the timely rebalancing of the portfolio.
Who Carisma Therapeutics competes with
Operating income before deduction of amortization argenx BVBA (ARGX)|BNTX - Profit before payment of interest, taxes and amortization|Abivax S.A. (ABVX) - Operating profit before deduction of amortization|ADMA Biologics, Inc. (ADMA) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Protagonist Therapeutics, Inc.|Operating profit before deduction of amortization IMVT|Operating profit EBITDA Kiniksa Corp|Profit before payment of interest, taxes and amortization Grifols, S.A. (GRFS)|adaptivebiotech.com - Operating profit before amortization|Operating profit EBITDA CLDX (Celldex Therapeutics, Inc.)|Aurinia Pharmaceuticals Inc (AUPH) - Profit before interest, taxes and amortization|BioCryst Pharmaceuticals Inc - Operating profit EBITDA|Vera Corp (VERA) - Operating profit before deduction of amortization|DNTH: Operating profit EBITDA|pharvaris.com (PHVS) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization AbCellera Biologics Inc.|TRML: Income before deduction of interest, taxes and amortization|Operating profit EBITDA PGEN|Operating income before deduction of amortization Pharming Corp|Profit before payment of interest, taxes and amortization Nektar Therapeutics NKTR|Operating income before deduction of amortization upstreambio.com (UPB)|ZBIO - Profit before payment of interest, taxes and amortization|Immunome Inc (IMNM) - Operating profit before deduction of amortization|GOSS: Operating profit EBITDA|KalVista Corp (KALV) - Operating profit EBITDA|Operating profit before deduction of amortization SEPN|PVLA: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization SVRA (Savara)|Company profit before taxes, interest and amortization RIGL|Operating profit EBITDA ANAB (AnaptysBio Corp)|Income before deduction of interest, taxes and amortization ATXS|enGene Holdings Inc. - Operating profit EBITDA|Profit before interest, taxes and amortization RAPT Therapeutics Inc.|aerovatetx.com (JBIO) - Profit before payment of interest, taxes and amortization|Aclaris Therapeutics Inc. - Income before deduction of interest, taxes and amortization|KYTX (Kyverna) - Operating profit EBITDA|Operating profit EBITDA Tiziana Life Sciences, Ltd.|Profit before payment of interest, taxes and amortization Cabaletta Bio, Inc. (CABA)|VTYX: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA THTX (Theratechnologies)|Avalo Therapeutics, Inc. (AVTX) - Profit before interest, taxes and amortization|ELDN: Operating profit before deduction of amortization|AGEN - Operating profit EBITDA|CLYM (Climb Bio Inc) - Operating profit before deduction of amortization|ZURA: Company profit before taxes, interest and amortization|ATYR (aTyr Pharma) - Operating profit EBITDA|Adagene Corp (ADAG) - Operating income before deduction of amortization|Operating profit EBITDA IMA|Operating profit before deduction of amortization shattucklabs.com STTK|Profit before payment of interest, taxes and amortization Equillium EQ|Operating income before deduction of amortization Connect Biopharma Holdings (CNTB)|Immunic Inc - Operating profit EBITDA|Atara Biotherapeutics (ATRA) - Operating profit before deduction of amortization|IFRX: Operating profit EBITDA|X4 Pharmaceuticals, Inc (XFOR) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Adicet Bio Inc.|CELU: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization INmune Bio (INMB)|Operating profit before deduction of amortization Barinthus Biotherapeutics PLC BRNS|Profit before payment of interest, taxes and amortization Kezar Life Sciences, Inc KZR|SABS (SAB Biotherapeutics Inc) - Profit before deduction of interest, taxes, depreciation and amortization|Akari Therapeutics - Operating profit EBITDA|Income before deduction of interest, taxes and amortization ENLV (Enlivex Therapeutics)|QTTB: Operating profit EBITDA|GeoVax Labs (GOVX) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Edesa|IBIO: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization XTL Biopharmaceuticals (XTLB)|Operating profit before deduction of amortization boltbio.com BOLT|Operating profit EBITDA HCWB (HCW Biologics)|Operating profit EBITDA Aptevo Therapeutics, Inc. APVO|AIM: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization ADTX (Aditxt)|GRI: Operating profit EBITDA|XRTX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Vyome Holdings|Operating profit before deduction of amortization Revelation Biosciences Inc (REVB)|Profit before payment of interest, taxes and amortization Indaptus (INDP)|Operating profit before deduction of amortization BiondVax Pharmaceuticals SCNI|CalciMedica - Operating profit before deduction of amortization|Operating profit EBITDA Affimed NV AFMD|ALLK - Profit before payment of interest, taxes and amortization|HOOK (HOOKIPA Pharma Inc.) - Operating profit before amortization|IGMS: Operating profit EBITDA|Profit before interest, taxes and amortization iTeos Pharma (ITOS)|OCEA (Ocean Biomedical, Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization tcbiopharm.com (TCBP)|Operating profit EBITDA THRD
